Loading clinical trials...
Loading clinical trials...
A Phase IIIB, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Clinical Efficacy Study of Baloxavir Marboxil for the Reduction of Direct Transmission of Influenza From Otherwise Healthy Patients to Household Contacts
Conditions
Interventions
Baloxavir Marboxil
Placebo
Locations
142
United States
Cahaba Research, Inc.
Birmingham, Alabama, United States
Cahaba Research, Inc
Pelham, Alabama, United States
Precision Trials
Phoenix, Arizona, United States
Hope Clinical Research
Canoga Park, California, United States
Long Beach Clinical Trials
Long Beach, California, United States
Downtown LA Research Center
Los Angeles, California, United States
Start Date
October 10, 2019
Primary Completion Date
May 10, 2024
Completion Date
May 10, 2024
Last Updated
July 4, 2025
NCT07291635
NCT06094010
NCT06417762
NCT06160128
NCT07396428
NCT07310472
Lead Sponsor
Hoffmann-La Roche
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions